Biocryst Pharmaceuticals Inc (BCRX) Stock Price & Analysis
Biocryst Pharmaceuticals Inc (BCRX) fell 1.29% to USD 9.96 as of September 8, 2026 at 09:36 UTC, according to Nexqual real-time market data.
BCRX last closed at USD 9.96; the session ranged USD 9.9–10.1 on volume of 1,495,739 shares. Market capitalization is —, with a 52-week range of USD 6–11.22 (NMS). Source: Nexqual, September 8, 2026 at 09:36 UTC.
Key Statistics (as of September 8, 2026 at 09:36 UTC)
| Price | USD 9.96 |
|---|---|
| Change | ▼ 1.29% (down) |
| Previous Close | USD 9.96 |
| Open | USD 9.96 |
| Day Range | USD 9.9 – 10.1 |
| 52-Week Range | USD 6 – 11.22 |
| Volume | 1,495,739 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (BCRX)
Nexqual's technical model rates BCRX "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 09:36 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 53.54 (neutral) |
| vs SMA50 | Above (USD 9.75) |
| MACD | 0.11 (positive) |
From Biocryst Pharmaceuticals Inc's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Based on proprietary analyses of HAE prevalence and market research studies with HAE patients, physicians, and payors in the United States and Europe, and five full years of commercialization experience with ORLADEYO in the United States from 2021 through 2025, we anticipate that the global commercial market for ORLADEYO has the potential to reach a global peak of $1 billion in annual net ORLADEYO revenues.
- In addition, we rely upon trade secrets and contractual arrangements to protect certain of our proprietary information, proprietary technology, and products and product candidates.
- Our ability to maintain and solidify our proprietary position for our technology will depend on our success in obtaining effective patent claims and enforcing those claims once granted.
- We own or have rights to certain proprietary information, proprietary technology, issued and allowed patents and patent applications which relate to compounds we are developing.
Partnerships
- Collaborations, License and Other Relationships ORLADEYO Torii Pharmaceutical Co., Ltd. ( " Torii " ) On November 5, 2019, we entered into a Commercialization and License Agreement with Torii (the "Original Torii Agreement"), granting Torii the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in Japan.
- On October 1, 2025, we also entered into a supply agreement with BioCryst Ireland, pursuant to which we will be the exclusive supplier of ORLADEYO products to BioCryst Ireland for commercialization in the territory.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | USD 28.02 | ▼ 3.15% |
| AGEN | Agenus Inc. | USD 8.24 | ▲ 1.85% |
| INO | Inovio Pharmaceuticals, Inc. | USD 1.43 | ▲ 5.15% |
| VXRT | Vaxart, Inc. | USD 0.5 | ▲ 2.04% |
| CERS | Cerus Corporation | USD 2.59 | ▼ 0.38% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 09:36 UTC. This page is informational and not investment advice.